Novel inhibitors of fatty acid oxidation as potential metabolic modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 4, 2004, Pages 973-977

  Elzein, Elfatih ^a   Shenk, Kevin ^a   Ibrahim, Prabha ^a   Marquart, Tim ^a   Kerwar, Suresh ^a   Meyer, Stephanie ^a   Ahmed, Hiba ^a   Zeng, Dewan ^a   Chu, Nancy ^a   Soohoo, Daniel ^a   Wong, Shirley ^a   Leung, Kwan ^a   Zablocki, Jeff ^a  

^a CV THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTIANGINA PECTORIS AGENT; BENZOTHIAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; FATTY ACID; PALMITOYL COENZYME A; PIPERAZINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; FATTY ACID OXIDATION; HEART MITOCHONDRION; INHIBITION KINETICS; ISOLATED HEART; METABOLISM; NONHUMAN; RAT; STABLE ANGINA PECTORIS;

ANGINA;

EID: 10744225943     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.11.065     Document Type: Article

References (28)

1. The American Heart Association. Biostatistical Fact Sheets. Dallas, TX: American Heart Association. 1997, p 1-29.
2. Gibbons R.J., Chatterjee K., Daley J. J. Am. Coll. Cardiol. 33:1999;2092.
3. Allely M.C., Alps B.J. Br. J. Pharmacol. 96:1989;977.
4. Opie L.H. The Heart: Physiology and Metabolism. 2nd ed. 1991;Raven, New York. p 208.
5. Boddeke E., Hugtenburger J., Jap W., Heynis J., Van Zweiten P. Trends Pharm. Sci. 10:1989;397.
6. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormak J.G. Cardiovasc. Res. 33:1997;243.
7. Hutter J.F., Piper H.M., Spieckermann P.G. Am. J. Physiol. 249:1985;H723.
8. Theroux P. Am. J. Cardiol. 83:1999;3. G.
9. Lopaschuk G.D., Wambolt R.B., Barr R.L. J. Pharm. Exp. Ther. 264:1993;135.
10. Anderson J.R., Siwhoung K., Nawarskas J.J. Heart Disease. 3:2001;263.
11. Pepine C.J., Wolff A.A. Am. J. Cardiol. 84:1999;46.
12. Schofield R.S., Hill J.A. Am. J. Cardiovasc. Drugs. 1:2001;23.
13. Jackson G. J. Cardiovasc. Drugs. 3:2003;27.
14. Wolff A., Rotmensch H., Stanley W. Heart Failure Reviews. 7:2002;187.
15. Conti C.R. Clin. Cardiol. 26:2003;161.
16. Ranolazine (CV Therapeutics Inc., Palo Alto, CA, USA) is currently being reviewed by the FDA for the treatment of stable angina. Trimetazidine has limited approval in Europe for the treatment of angina.
17. MacInees A., Fairman D., Binding P., Rhodes J., Wyatt M., Phelan A., Haddock P., Karran E. Cir. Res. 93:2003;270.
18. Fraser H., McVeigh J., Ibrahim P., Blackburn B., Belardinelli L. J. Am. Coll. Cardiol. 41(6):2003;253A.
19. Baldwin J.J., Raab A.W., Mensler K., Arison B.H., McClure D.E. J. Org. Chem. 43:1978;4876.
20. McClure D.E., Arison B.H., Baldwin J.J. J. Am. Chem. Soc. 101:1979;3666.
21. Mclure D.E., Engelhardt E.L., Mensler K., King S., Saari W.S., Huff J.R., Baldwin J.J. J. Org. Chem. 44:1979;1826.
22. Shiratsuchi M., Kiyoshi K., Toshihiro A., Hiroshi I., Masaki N., Takenaka F. Chem. Pharm. Bull. 35:1987;3691.
23. Caroon J.M., Clark R.D., Kluge A.F., Nelson J.T., Strosberg A.M., Unger S.H., Michel A.D., Whiting R.L. J. Med. Chem. 24:1981;1320.
24. Chang J., Zhao K., Pan S. Tetrahedron Lett. 43:2002;951.
25. Boger D. J. Org. Chem. 43:1978;2296.
26. Elzein, E.; Chu, N.; Soohoo, D. Unpublished results, CV Therapeutics Inc., Palo Alto, CA.
27. Lin J.H., Lu A. Clin. Pharmacokinet. 35:1998;361.
28. 50=180 nM, liver S-9 stability of 50%, oral bioavailabiliy of 30% and 42% in rats and dogs, respectively.